We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Device Proven in the Field

By LabMedica International staff writers
Posted on 03 Jul 2014
A blood testing platform has been introduced that accommodates test strips for a wide variety of conditions from celiac disease, allergy through to infectious diseases such as malaria and human immunodeficiency virus (HIV).

The blood test device AtomoRapid HIV has been awarded Best in Show, and the winner of the In Vitro Diagnostics Category, at the Medical Design Excellence Awards (MDEA), held June 11, 2014, in New York (NY, USA).

Image: The AtomoRapid device for testing for human immunodeficiency virus (HIV) (Photo courtesy of Atomo Diagnostics).
Image: The AtomoRapid device for testing for human immunodeficiency virus (HIV) (Photo courtesy of Atomo Diagnostics).

The company that manufactures the AtomoRapid device is Atomo Diagnostics (Sydney, Australia) is an award-winning based healthcare company with a focus on product development and usability. Atomo develops and commercializes next generation solutions that address unmet user needs in the diagnostic industry.

The AtomoRapid HIV test uses a World Health Organization (WHO; Geneva, Switzerland) prequalified, antibody test for the detection of HIV 1&2 in human whole blood, serum or plasma. It is a highly sensitive screening test that performs well when deployed in the field. Given its ease of use and simplicity, AtomoRapid HIV has the ability to materially improve both the uptake and reliability of HIV testing in the community and at home. AtomoRapid HIV test is currently available for sale in several African countries from their South Africa office. AtomoRapid Malaria, the second test to market, will be available in the 3rd Quarter of 2014 and they plan to introduce additional tests in the coming 18 months.

John Kelly, B.Eng, MSc, EMBA, Founder and CEO of Atomo Diagnostics, said, “Clinical performance of standard test kits is proven in the laboratory, but serious concerns have been raised about in-field performance. This is down to their complex nature, requiring multiple components for the procedure offering resulting in errors, which in turn creates false diagnosis. For a disease such as HIV, this can have significant impact not only on the individual, but the community too.”

Related Links:

Medical Design Excellence Awards 
Atomo Diagnostics



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Latest Technology News

New Diagnostic System Achieves PCR Testing Accuracy

DNA Biosensor Enables Early Diagnosis of Cervical Cancer

Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples